
News|Videos|October 17, 2023
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series

This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
2
FDA clears Revi Extend implant for urgency urinary incontinence
3
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
4
FDA updates in urology: July 2026
5














